ReviewBiochimica et biophysica acta2010
Targeted drug delivery in pancreatic cancer.
Review in Biochimica et biophysica acta, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- Anti-EGFR liposomal drug delivery system loaded with AGYInternational journal of pharmaceutics: X · 2026Article
- Prospect of Gold Nanoparticles in Pancreatic Cancer.Pharmaceutics · 2024Review
- Deciphering the role of NcRNAs in Pancreatic Cancer immune evasion and drug resistance: a new perspective for targeted therapy.Frontiers in immunology · 2024Review
- Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.Pharmaceutics · 2023Review
- Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.Acta biomaterialia · 2021Article
- New insights on the role of autophagy in the pathogenesis and treatment of melanoma.Molecular biology reports · 2020Review
- Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.Molecular biology reports · 2020Article
- Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.Molecular cancer research : MCR · 2020Article
- Article
- Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.Bulletin of mathematical biology · 2019Article
- Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment.Cancer science · 2018Review
- Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2018Article
- Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.Molecules (Basel, Switzerland) · 2018Review
- Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice.Molecular therapy. Methods & clinical development · 2018Article
- Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.Scientific reports · 2018Article
- Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.Oncotarget · 2018Article
- Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe.Molecular cancer research : MCR · 2017Article
- Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials.Biomedicines · 2016Review
- Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Effective drug delivery in pancreatic cancer treatment remains a major challenge. Because of the high resistance to chemo and radiation therapy, the overall survival rate for pancreatic cancer is extremely low. Recent advances in drug delivery systems hold great promise for improving cancer therapy. Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials. However, how to improve the specificity and stability of the delivered drug using ligand or antibody directed delivery represent a major problem. Therefore, developing novel, specific, tumor-targeted drug delivery systems is urgently needed for this terrible disease. This review summarizes the current progress on targeted drug delivery in pancreatic cancer and provides important information on potential therapeutic targets for pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.